Literature DB >> 9531328

The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells.

M Jourdan1, M Ferlin, E Legouffe, M Horvathova, J Liautard, J F Rossi, J Wijdenes, J Brochier, B Klein.   

Abstract

Syndecan-1 is a cell membrane proteoglycan that binds extracellular matrix components and various growth factors. It is expressed only on malignant plasma cells in bone marrow samples from patients with multiple myeloma (MM). Several reports have suggested that syndecan-1 was present only on a part of the myeloma cells. By using either IL-6-dependent myeloma cell lines or primary myeloma cells stained by annexin V, we report here that syndecan-1 was rapidly lost by myeloma cells undergoing apoptosis. In the same experimental conditions, expression of other cell membrane antigens such as CD38, HLA class-I or CD49d on apoptotic myeloma cells was not affected. In addition, we show that syndecan-1 loss was independent of activation of the gp130 IL-6 transducer. Dexamethasone induced a strong apoptosis of myeloma cells associated with the loss of syndecan-1. Finally, by using freshly-explanted tumoural samples, we show that syndecan-1 rapidly disappeared from myeloma cells in association with induction of apoptosis. In conclusion we showed that syndecan-1 is a marker for viable myeloma cells which is rapidly lost by apoptotic cells. These results emphasize the usefulness of anti-syndecan-1 antibodies to purge tumoural cells from haemopoietic grafts or to purify these cells for further manipulations for immuno or gene therapies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9531328     DOI: 10.1046/j.1365-2141.1998.00623.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  33 in total

1.  Characterization of potential CD138 negative myeloma "stem cells".

Authors:  Jacob H Christensen; Pia V Jensen; Ida B Kristensen; Niels Abildgaard; Marianne Lodahl; Thomas Rasmussen
Journal:  Haematologica       Date:  2012-06       Impact factor: 9.941

2.  EBV-positive plasmacytoma of the submandibular gland--report of a rare case with molecular genetic characterization.

Authors:  Benedict Yan; Soo Yong Tan; Ee Xuan Yau; Siok Bian Ng; Fredrik Petersson
Journal:  Head Neck Pathol       Date:  2011-03-26

3.  Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients.

Authors:  Caroline Rousseau; Ludovic Ferrer; Stéphane Supiot; Manuel Bardiès; François Davodeau; Alain Faivre-Chauvet; Pierre Baumgartner; John Wijdenes; Marie Lacombe; Jacques Barbet; Thierry Guillaume; Philippe Moreau; Jean Luc Harousseau; Françoise Kraeber-Bodéré; Michel Cherel
Journal:  Tumour Biol       Date:  2012-03-03

Review 4.  Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.

Authors:  Kah Teong Soh; Joseph D Tario; Paul K Wallace
Journal:  Clin Lab Med       Date:  2017-12       Impact factor: 1.935

5.  Tumor necrosis factor is a survival and proliferation factor for human myeloma cells.

Authors:  M Jourdan; K Tarte; E Legouffe; J Brochier; J F Rossi; B Klein
Journal:  Eur Cytokine Netw       Date:  1999-03       Impact factor: 2.737

Review 6.  What we mean when we talk about MRD in myeloma. A review of current methods. Part 1 of a two-part series.

Authors:  Scott Ely; Noa Biran; Ajai Chari
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

7.  Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells.

Authors:  Caroline Bret; Dirk Hose; Thierry Reme; Anne-Catherine Sprynski; Karène Mahtouk; Jean-François Schved; Philippe Quittet; Jean-François Rossi; Hartmut Goldschmidt; Bernard Klein
Journal:  Br J Haematol       Date:  2009-03-02       Impact factor: 6.998

8.  Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.

Authors:  A Seckinger; T Meissner; J Moreaux; H Goldschmidt; G M Fuhler; A Benner; M Hundemer; T Rème; J D Shaughnessy; B Barlogie; U Bertsch; J Hillengass; A D Ho; V Pantesco; A Jauch; J De Vos; J F Rossi; T Möhler; B Klein; D Hose
Journal:  Oncogene       Date:  2009-08-31       Impact factor: 9.867

9.  Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo.

Authors:  Rodger E Tiedemann; Jessica Schmidt; Jonathan J Keats; Chang-Xin Shi; Yuan Xiao Zhu; Stephen E Palmer; Xinliang Mao; Aaron D Schimmer; A Keith Stewart
Journal:  Blood       Date:  2008-12-18       Impact factor: 22.113

Review 10.  Syndecan-1: a dynamic regulator of the myeloma microenvironment.

Authors:  Ralph D Sanderson; Yang Yang
Journal:  Clin Exp Metastasis       Date:  2007-11-20       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.